SAN FRANCISCO, Nov. 7, 2024 — The Nursing Beat, the leading daily digital newsletter designed for nurses by nurses, today announced the first close of an equity funding round. This milestone investment underscores the growing recognition of nurses as crucial influencers in healthcare and validates The Nursing Beat’s innovative approach to delivering targeted, relevant information to healthcare professionals.

Led by two former ER nurses, Tamara AL-Yassin and Hannah W. Berns, The Nursing Beat has rapidly become an essential resource and the daily pulse for healthcare professionals across its email newsletter, social media community, and bespoke events. This funding round, supported by investors including Nurse Capital and Cherrystone Angel Group, will fuel The Nursing Beat’s mission to keep nurses informed, engaged, and empowered in their careers.

“This investment is a testament to the critical role nurses play in shaping the future of healthcare,” said Tamara AL-Yassin, CEO of The Nursing Beat. “We’re growing more than a media platform. We’re nurturing a community that amplifies the collective voice of nurses and drives positive change in healthcare delivery. And we are thrilled to welcome Nurse Capital into our investor community.”

Beth A. Brooks, PhD, RN, Co-Founder and General Partner of Nurse Capital, expressed enthusiasm for the investment: “The Nursing Beat exemplifies the kind of nurse-led innovation we’re passionate about supporting. By providing crucial, timely information to nurses, they’re empowering individual professionals and driving systemic improvements in healthcare. This aligns perfectly with our mission to disrupt the nursing care ecosystem positively.”

The investment also marks a continued partnership with connectRN, a platform that empowers nurses and nursing professionals to take control of their careers. Ted Jeanloz, CEO of connectRN, commented on the significance of the funding: “Our continued backing of The Nursing Beat reflects our unwavering belief in the power of informed, connected nurses. This platform is reshaping how nurses perceive their role in the healthcare ecosystem. We’re proud to support a venture that is elevating the nursing profession.”

The new funding will enable The Nursing Beat to:

• Enhance its content offerings and expand into new media formats
• Invest in advanced technology to deliver more personalized news experiences
• Expand its team of healthcare experts and content contributors
• Develop new features to foster community engagement and networking among nurses
• Explore partnerships to provide additional value-added services to its audience

For more information about The Nursing Beat and its mission to empower nurses through information, please visit https://thenursingbeat.com/

About The Nursing Beat:
The Nursing Beat is the only daily digital newsletter designed for nurses, by nurses. Led by two former ER nurses, The Nursing Beat delivers concise, relevant news and essential information to help nurses stay informed and empowered in their careers. The Nursing Beat reaches nurses and allied healthcare professionals across its flagship email newsletter, social media community, and bespoke events. The Nursing Beat is revolutionizing how healthcare professionals stay connected and informed in an ever-changing industry.

About Nurse Capital
Nurse Capital is a women-founded and managed venture capital fund based in Chicago that makes early-stage investments in nurse entrepreneurs leading high-growth-potential businesses that are transforming the future of healthcare. Learn more at https://nursecapital.net/.

SOURCE The Nursing Beat

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

BOSTON, Nov. 7, 2024 — Parallel Fluidics, the fastest microfluidic device manufacturer in the world, announced the close of its $7M seed round, led by J2 Ventures with participation from 8VC and Praxis. The funding will help drive the growth of the company’s on-demand design and manufacturing platform, expand its hardware and software solutions, and commercialize its new product, MV-2.

Diagnostics, drug discovery, precision medicine, sequencing, and cell therapy verticals are quickly shifting towards microfluidics, a technology where scientific tests can run at microscopic scales, allowing life science companies to achieve the next level of precision, speed, and throughput. Today, the global microfluidics market is a $32B industry currently and is expected to reach $117.13B by 2031 but is held back by design and supply chain challenges.

“Scientists and engineers developing the next breakthrough life science technology shouldn’t be forced to reinvent the wheel when it comes to microfluidic systems, especially in applications like point-of-care diagnostics,” said Jon Bronson, PhD, Managing Partner and co-founder of J2 Ventures. “With clients including academic labs, venture-backed startups and large biotech companies, Parallel Fluidics is making a huge impact with its on-demand microfluidic manufacturing services. Their products eliminate the common development risks, and accelerate the timeline from concept to launch by delivering production-ready devices in as little as three days – a true game changer for time-sensitive, cost-effective R&D.”

“While more life science products are built with microfluidics, scientific teams have historically struggled with engineering and manufacturing challenges unrelated to their novel technology, such as flow control, automation, and the chip-to-world interface, said Josh Gomes, CEO and co-founder of Parallel Fluidics. “At Parallel Fluidics, we are on a mission to help scientific teams build scalable and reliable products to identify diseases faster and develop more effective medicines. With the new funding, we’ll be able to scale up our on-demand manufacturing service, expand our hardware library, and develop new design and analytics software to power the next generation of life science tools.”

Parallel Fluidics’ hardware library offers an array of off-the-shelf hardware solutions to solve engineering challenges in microfluidics, reducing the cost and time for customers to develop new products. The MV-2 is Parallel’s latest addition, an innovative microvalve that enables products to work at the point-of-care, like a doctor’s office, clinic, or hospital, instead of only in laboratory environments. Overture Life, an exciting life science startup simplifying in-vitro fertilization procedures, is using the MV-2 to control flow in their next-generation system.

“In order to provide advanced care in fertility treatments such as IVF, precise fluid control and the ability to manage sensitive biological samples without being wasteful are critical. Solutions like Parallel Fluidics’ microfluidic systems are filling that gap with their microvalves and enabling faster, more reliable processes that can help us enhance patient outcomes and drive innovation in reproductive medicine,” said Lionel Matthys, Chief Product Officer, Overture Life.

About Parallel Fluidics
Parallel Fluidics accelerates the pace of discovery for scientific teams with the world’s first on-demand microfluidic manufacturing service. By offering production-grade devices from day one, Parallel eliminates the risks that slow down development and provides the shortest path from a concept to a successful microfluidic product. Parallel Fluidics is already making a transformative impact across life sciences verticals such as diagnostics, drug discovery, precision medicine, sequencing, and cell therapy – empowering innovators to accelerate breakthroughs and improve patient outcomes. For more information about Parallel Fluidics, visit www.parallelfluidics.com.

About J2 Ventures
J2 Ventures is a $250M+ AUM deep-tech venture capital firm based in Boston, investing in sectors critical to national security and private sector advancements, including advanced computing, cybersecurity, telecom and infrastructure, and biomedical engineering. For more information about J2 Ventures and its initiatives, please visit https://www.j2vp.com/.

Media Contact:
Liang Zhao
Vansary for Parallel Fluidics
[email protected]
505-720-6933

SOURCE Parallel Fluidics

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

 Adds Dr. Erez Agmoni, Former Maersk Head of Innovation, as General Partner

NEW YORK, Nov. 7, 2024 — Interwoven Ventures (Interwoven), an early-stage venture capital firm investing in groundbreaking technologies across robotics and artificial intelligence (AI) to transform industries including manufacturing, logistics, transportation, and healthcare, proudly announces the appointment of Dr. Erez Agmoni as co-founder and General Partner. A globally recognized leader in technological innovation, Agmoni brings a wealth of expertise in AI, robotics, and digital transformation, and will help propel Interwoven’s mission of empowering early-stage companies to innovate and excel.

Interwoven Ventures, spun-out from ROBO Global, continues the legacy established by partners Lisa Chai, Clay Shepherd, Dr. Henrik Christensen and Richard Lightbound. With the addition of Agmoni, Interwoven further strengthens its ability to leverage investment acumen and technical expertise to identify and support companies developing advanced technologies to drive innovation and transform traditional industries. Technology startups mentored by Interwoven are harnessing the power of AI and robotics to achieve new levels of sustainable growth and efficiency across sectors like food and agriculture, healthcare, construction and industrial manufacturing.

Dr. Agmoni’s career spans more than 25 years of operational leadership, distinguished by roles that have championed data-driven solutions, advanced AI applications, and the strategic integration of robotics to optimize complex networks. At Maersk, he was instrumental in spearheading digital and automation innovations, enhancing transparency, and improving efficiency across the global supply chain ecosystem. His work established benchmarks in leveraging technology to drive operational agility and sustainability.

“Erez is a visionary leader with the rare combination of deep technological knowledge, practical operational expertise, and a collaborative spirit,” said Lisa Chai, co-founder and General Partner of Interwoven Ventures. “At ROBO Global, we saw firsthand the transformative potential of AI and robotics. With Erez joining us, Interwoven is uniquely positioned to guide disruptive startups in navigating challenges and scaling solutions that can reshape industries.”

“I am thrilled to join Interwoven Ventures and contribute to its pioneering work in fostering innovation at the intersection of AI and robotics,” said Agmoni. “Throughout my career, I’ve been driven by a passion for developing smarter, more sustainable solutions to industry challenges. I am eager to collaborate with founders and entrepreneurs who are redefining the future of business with groundbreaking technologies.”

About Interwoven Ventures

Interwoven Ventures is an early-stage venture capital firm specializing in robotics and AI, with a focus on transformative opportunities in industries like manufacturing, logistics, transportation, and healthcare. Since its inception in 2022 as an incubated venture of ROBO Global, the firm has been committed to leveraging decades of industry and operational expertise to empower visionary entrepreneurs and build a foundation for long-term success and innovation. For more information, please visit interwoven.vc.

SOURCE Interwoven Ventures

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

NATIONAL HARBOR, Md., Nov. 7, 2024 — Knexus, a leading provider of artificial intelligence (AI) solutions, announced today that it has closed an equity investment from Scare the Bear Capital, an investment firm focused on driving growth within the small business community. 

Over the past year, Knexus has made strides in leveraging its past performance and expertise in AI solutions to help government entities incorporate AI methods and capabilities into their workflow.  Knexus’ partnership with Google has enabled the company to rapidly develop AI solutions, demonstrating to government customers how the combination of Knexus’ expertise with Google’s commercial grade technology shows how government entities can extract value from AI.

“In 2023, we rolled out our Knexus 2.0 strategy, building on the foundation of the company’s 17 year history, and wrapping our AI expertise around the Google AI Tech Stack,” said Knexus CEO Adam Lurie.  “Our approach has not just yielded results, but drove demand at a pace where we knew we needed a partner.  Scare the Bear Capital is perfect.  Our collective vision for the company aligns and we are excited to move forward with them by our side.”

Scare The Bear Capital targets GovCon companies with the potential to grow, improve their operations, and ultimately compete and win larger, more significant contract opportunities. Knexus’ recent contract win at the DLA is a demonstration of the company’s ability to deliver on its strategy.

“Knexus has demonstrated exceptional execution and a deep understanding of the market, “said Matthew Dean, Scare the Bear Managing Partner.  “We are proud to be part of their journey and look forward to helping them scale the company.”

This strategic investment positions Knexus to further capitalize on the growing demand for AI solutions within the government sector. By combining Scare the Bear Capital’s resources and expertise with Knexus’ technical capabilities and track record of innovation, the company is poised for significant expansion in delivering cutting-edge AI solutions to solve the government’s toughest challenges.

About Knexus

For nearly two decades, Knexus has worked with dozens of agencies across the US Government as a trusted partner to deliver tailored AI solutions to mission-critical problems. With four patents and 100+ peer reviewed scientific papers, the scientists and engineers of Knexus are routinely smashing through the barriers between human and machine intelligence.  As a Google Cloud partner, Knexus offers its customers expertise in working with Google Cloud’s AI products, such as the Vertex AI platform and Gemini models to deliver AI solutions to the public sector.  

About Scare the Bear Capital

Scare the Bear Capital (STB) is a private investment firm focusing on small to mid-tier businesses. Scare the Bear provides capital combined with focused advisory support to partner with small businesses, helping them show the strength and maturity of mid to large size companies. Value is created through focusing on 12 value drivers.  Businesses can then command the level of valuation typically reserved for their larger counterparts.

SOURCE Knexus

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

VIGO, Spain and LONDON, Nov. 7, 2024 — Marosa 2024 S.L. (“Marosa”), a leading provider of VAT compliance and e-invoicing technology solutions, today announced it has secured a €12 million investment from Aquiline, a private investment firm specializing in financial services and technology. This funding represents Marosa’s first external capital raise and will help accelerate its growth strategy, expand compliance software and e-invoicing offerings, and support its global expansion.

Founded in 2016 by Pedro Pestana da Silva, Marosa is a tech-enabled provider of mission-critical VAT compliance technology and services, catering to large multinational business customers with VAT filing obligations across Europe. With over 1,200 enterprise and eCommerce customers, Marosa’s flagship software, VATify, offers a cloud-based, end-to-end solution that centralizes e-invoicing, VAT registration, and reporting. The company also provides real-time reporting of e-invoices in response to regulatory requirements in various EU countries.

The investment from Aquiline will enable Marosa to further accelerate product development, go-to-market approach, and international expansion, while capitalizing on significant regulatory and market momentum across Europe. Recent regulatory shifts, such as the adoption of mandatory e-invoicing and real-time reporting across Europe, have underscored the importance of digital VAT compliance solutions. Marosa is at the heart of these requirements, as it helps large multinational enterprises seeking to get ahead of regulatory changes by digitizing e-invoicing and VAT processes.

Pedro Pestana da Silva, Founder and CEO of Marosa, commented:

“I am delighted to welcome Aquiline as our first external investor. Over time, we have built a trusted relationship with their team, and they truly understand our vision, technology, and the needs of our clients. With this investment, we are well prepared to accelerate our R&D, enhance our product offerings, and expand our reach in a complex and evolving market.”

Giovanni Nani, Principal at Aquiline, added:

“Since our first meeting in 2020 we have admired the software and services that Pedro and the Marosa team have been developing for their growing customer base in an increasingly complex regulatory environment. Aquiline has a strong track record of backing bootstrapped financial services and technology entrepreneurs. We are excited to partner with Marosa on its next phase of growth and support the team on its journey of becoming a pan-European VAT compliance and e-invoicing leader.”

Notes to Editors

About Marosa

Marosa is a leading provider of fully integrated VAT compliance and e-invoicing technology solutions, serving enterprise and eCommerce clients across Europe. Headquartered in Vigo, Spain, Marosa’s flagship software, VATify, centralizes e-invoicing, VAT registration, and reporting, and automates communication with tax authorities, helping businesses stay ahead of regulatory changes and streamline their VAT compliance processes.

For more information, visit www.marosavat.com.

About Aquiline

Aquiline Capital Partners LP (“Aquiline”) is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of September 30, 2024, Aquiline has approximately $11.3 billion of assets under management and has deployed approximately $7.0 billion of capital across the firm’s three strategies in private equity, venture, and credit.

For more information about Aquiline, its investment professionals, and its portfolio companies, visit www.aquiline.com.

Logo – https://mma.prnewswire.com/media/2550642/Aquiline_logo.jpg

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

Fintech leader strengthens position in cross-border B2B payments and trade finance, eyeing rapid growth across Asia, including China and India

AMSTERDAM and SINGAPORE, Nov. 6, 2024 — MODIFI, a leading global platform in B2B Buy Now, Pay Later (BNPL) solutions, today announced the successful completion of a $15 million funding round led by SMBC Asia Rising Fund with participation from existing investors Maersk, IntesaSanPaolo, Heliad and other top-tier global investors. Sumitomo Mitsui Banking Corporation (SMBC), one of Japan’s leading banks and a major financial force in the APAC region, brings both capital and strategic alignment to the partnership. Beyond the equity investment, MODIFI and SMBC have signed a Memorandum of Understanding (MoU) to jointly advance digital solutions that support SME exporters across Asia in expanding their international trade operations. Through a series of joint initiatives, MODIFI and SMBC aim to empower SMEs with innovative cross-border financing solutions.

The announcement comes on the sidelines of Singapore Fintech Festival, showcasing MODIFI’s drive for innovation in the global fintech landscape. This new capital infusion will accelerate MODIFI’s expansion, particularly in high-growth markets like China and India, where the company has already made significant inroads. MODIFI’s platform delivers critical liquidity and flexible payment terms to small and medium-sized enterprises (SMEs), helping them optimize cash flow and expand their international reach.

“The funding underscores the strength of our business and the confidence our investors have in our vision for the future,” said Nelson Holzner, CEO and Co-founder of MODIFI. “As global commerce evolves, MODIFI is at the forefront, providing innovative solutions that empower businesses to scale and succeed across borders.”

MODIFI’s exponential growth has solidified its position as a market leader in cross-border payments and trade finance. Recognized by Financial Times and Statista as one of the Fastest Growing European Fintech Companies in 2024, MODIFI has facilitated over $3 billion in global trade for more than 1,800 companies since it was founded in 2018. The platform offers instant working capital approval, alongside integrated risk management tools that shield businesses from buyer defaults and fraud.

“Our mission is simple: We empower SMEs to compete and thrive in the global market with fast, flexible, and secure payment solutions,” added Holzner. “With this fresh funding, we’re set to redefine global trade finance—ensuring businesses of all sizes can unlock the liquidity and get the protection they need to grow internationally.”

“By transforming cross-border supply chain finance for the digital age with their global presence, we believe MODIFI supports SMEs to scale their export businesses with ease. We look forward to collaborating with MODIFI to empower our corporate clients to expand their businesses globally with agility and financial flexibility overcoming traditional trade barriers,” said Keiji Matsunaga, General Manager of Digital Strategy Department, SMBC.

About MODIFI

MODIFI is redefining global trade finance as a leader in B2B Buy Now, Pay Later (BNPL) solutions. Trusted by businesses across 55+ countries, MODIFI provides cutting-edge tools that optimize working capital and streamline cross-border payments. Through its extensive global network, MODIFI delivers fast, flexible, and secure financial solutions, helping companies expand their international footprint with ease. By integrating advanced risk management features and seamless payment processes, MODIFI is setting new benchmarks in global commerce, empowering businesses of all sizes to thrive in a rapidly evolving market.

About SMBC and SMBC Asia Rising Fund

SMBC, one of the leading banks in Japan, co-funded SMBC Asia Rising Fund with Incubate Fund which is a corporate venture capital fund, for the purpose of accelerating business development and partnerships through investments in high potential start-ups operating actively in Asia. Through this fund, SMBC Group will enhance its business and provide clients with new solutions by uncovering/ applying new technologies via partnerships with investee firms and the development of new business models and products.

Photo: https://mma.prnewswire.com/media/2549272/MODIFI_Strategic_Investment.jpg
Logo: https://mma.prnewswire.com/media/2549327/Modifi_Logo.jpg

SOURCE MODIFI B.V.

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

NEW YORK, Nov. 5, 2024 — Research Grid, the AI startup that helps medical research institutions automate back-office admin for clinical trials, has raised a $6.5m seed round. The company will use the new funding to double down on its mission of making clinical trials faster and more successful.

The round was led by Fuel Ventures, with participation from Arve Capital, Ada Ventures, Morgan Stanley Inclusive Ventures Lab, Arāya Ventures, Ascension Ventures, Plug and Play Ventures, and Atomico Angels, with limited availability remaining.  

With artificial intelligence poised to rapidly accelerate the speed of drug discovery, the funding comes at a critical time for the clinical trials market, which is now seen as the major bottleneck in the drug development process. This is often caused when using legacy software systems and manual processes to manage trials, resulting in inefficiency, errors, and weak patient engagement. Delays to clinical trials are also phenomenally expensive, costing up to $400 million per year, per trial running to Phase 3, just on back-office admin.

To solve this problem, Research Grid has developed two products, Inclusive and TrialEngine, which together allow its customers to seamlessly manage the full life cycle of clinical trials in one place.

Both products are powered by Research Grid’s patented-pending AI algorithms which automate many of the administrative and data management workflows. This eliminates the monotonous work, freeing up highly qualified medical researchers to focus on more meaningful work.

Research Grid helps its customers cut months off trial timelines while dramatically reducing their costs and driving up success rates. On average, customers of Research Grid see 98% efficiency gains, 45% cost savings, and 145% increase in patient engagement.

The company will use the funding to invest in R&D, developing more AI automations and building out its engineering teams. It also plans to grow its marketing and sales functions as it expands its presence in US and Asian markets.

Products built from first-hand experience

The company was founded by Dr Amber Hill, a former medical researcher with a PhD in biomedical neuroscience and a background in AI research technology. This first-hand experience of the clinical trials means she was uniquely positioned to build a solution, with a deep understanding of the problem.

The recruitment phase is a common source of delays in clinical trials, due to the extremely manual process of sourcing representative samples of patients which are often sourced via adverts on social media. Increased pressure from the FDA to ensure representative patient panels means this has become increasingly important.

Research Grid’s Inclusive product, a patient recruitment and engagement platform, largely solves this problem, providing instant access to a vetted network of more than 91,000 global communities covering 2,050 medical conditions. It also automates all the admin, such as patient outreach, payments, and data management. 

The TrialEngine product, which connects seamlessly with Inclusive, handles the administration, data, and reporting workflows during the trial itself. It leverages Research Grid’s AI algorithms to automate tasks such as protocol generation and data extraction.

Dr Amber HIll, Founder and CEO of Research Grid, said: 

“I spent 14 years as a medical researcher, and I would spend hundreds of hours copying data from one system to another. The back-office process is completely broken. When you multiply this across the industry the costs for patients and research institutions are astronomical.  

“That’s why we’re building the automation engine for admin-free clinical trials. Whether you’re a pharmaceutical company, a CRO, or a clinical research site, we can help run faster, more successful clinical trials. We’ve already seen how AI is accelerating drug discovery and it’s time to do the same in clinical trials.

“We’re delighted to have the support of our investors. Now we’re focusing on expanding our engineering teams and scaling up our R&D efforts, allowing us to deliver more of the features our customers are asking for. We’ll also be growing our sales and marketing team so that we can take advantage of opportunities in the US and Asia.”

Shiv Patel, Partner at Fuel Ventures, said:

“We are committed to backing the most innovative and disruptive businesses in the country, and our investment into Research Grid reinforces this.

“While AI is making significant waves in drug discovery, clinical trials are still the main barrier to medicine reaching the people who need it, and Research Grid is strategically placed to exploit the urgent demand of automating clinical trials at scale. Its rapid growth has shown that the market is largely green-field, with validation from across the industry in the U.S. and Europe, including big pharma, contract research organisations and sites.

“Every investor wants to find unicorns, and with the clinical trial market expected to reach over $95 billion in the next five years, we believe in the mission, proposition and trajectory of Research Grid.”

SOURCE Research Grid Ltd

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

• Serie B-financiering van $ 27,3 miljoen mede geleid door Kibo Invest en Openspace, met verdere deelname van MTR Lab, Taronga Ventures en 2150
• Ampd Energy heeft meer dan 300 slimme batterijeenheden in meer dan zeven landen ingezet, voornamelijk in de bouw. Daarmee heeft het meer dan 69.000 ton CO₂ verminderd, het equivalent van 88.000 auto’s
• In 2025 wil het uitbreiden naar nieuwe markten (mijnbouw en industrie) en regio’s (Europa, het Midden-Oosten, Zuidoost-Azië en de VS)

SINGAPORE, 5 november 2024 — Ampd Energy, een wereldwijde innovator in de energie-industrie en fabrikant van de Enertainer en Ampd Silo™ batterij-energieopslagsystemen (ESS) voor zware industrieën, kondigt vandaag aan dat het 27,3 miljoen dollar heeft opgehaald in een overtekende Serie B-financieringronde. De ronde werd mede geleid door Kibo Invest en Openspace, de grootste investeerder in deze ronde, met opmerkelijke deelname van bestaande investeerders MTR Lab, Taronga Ventures en 2150. Zij benadrukten hun steun en geloof in Ampd Energy door hun pro ratabelang te overschrijden. De fondsen zullen worden gebruikt om decarbonisatie naar nieuwe sectoren en regio’s uit te breiden.

Volgens de International Energy Agency (IEA) is de gecombineerde bouwsector verantwoordelijk voor 30% van het totale wereldwijde eindverbruik van energie en 27% van de totale uitstoot in de totale energiesector. In vergelijking met generatoren die op fossiele brandstoffen werken, verminderen de energieopslagproducten Ampd Silo en Enertainer de koolstofvoetafdruk met wel 90%, zijn ze aanzienlijk stiller, stoten ze geen luchtverontreinigende stoffen uit en elimineren ze de risico’s van het omgaan met en het gebruik van diesel.

Door te focussen op technische innovatie en commerciële haalbaarheid, heeft het bedrijf tot nu toe meer dan 300 units in zeven landen ingezet, voornamelijk in de bouw. Daarbij heeft het meer dan 69.000 ton CO₂ verminderd, wat gelijk staat aan het van de weg halen van meer dan 88.000 auto’s. De recente financiering vond plaats in een uitdagende fondsenwerving. De finalist van de 2022 Earthshot Prize is van plan deze te gebruiken om in 2025 uit te breiden naar nieuwe markten zoals mijnbouw en productie. De opbrengst gaat ook naar nieuwe regio’s, waaronder het Midden-Oosten, Europa, de Verenigde Staten en Zuidoost-Azië, ondersteund door de nieuwe samenwerking met Kibo Invest en Openspace.

“Deze nieuwe financiering is een bewijs van het harde werk van ons team. Het leveren van een commercieel levensvatbare schonere oplossing aan bedrijven wereldwijd staat bij ons centraal, waarbij onze investeerders zich inspannen om een emissievrije toekomst voor industrieën te realiseren,” aldus Anthony Stewart, CFO bij Ampd Energy. “We kijken uit naar het versnellen van onze groei, zodat wij nieuwe verticale markten kunnen betreden en nog meer innovatieve oplossingen aan onze klanten wereldwijd kunnen bieden.”

“We zijn bijzonder onder de indruk van het visionaire leiderschap van Ampd Energy en zijn scherpe focus op het uitvoeren van een duidelijke strategische routekaart,” zegt James Marshall, CEO van Kibo Invest. “Dit streven naar uitmuntendheid komt overeen met onze eigen beleggingsfilosofie. We vinden het heel spannend om Ampd Energy’s uitbreiding naar nieuwe markten en industrieën te ondersteunen, verdere groei te stimuleren en zijn positieve invloed op het wereldwijde energielandschap te vergroten. Bij Kibo Invest zijn we toegewijd aan het investeren in vooruitstrevende bedrijven die de toekomst vormgeven. Ampd Energy is een uitstekend voorbeeld van die visie in actie.”

Jessica Huang Pouleur, partner bij Openspace, beaamt dit. “We zijn blij dat we Ampd Energy kunnen steunen. Tot op vandaag heeft het een grote dynamiek getoond en het staat nog aan de wieg van zijn enorme potentieel om zijn energieopslagoplossingen in Zuidoost-Azië en wereldwijd te realiseren. De ruggengraat van het bedrijf wordt gevormd door een toegewijd en sterk managementteam, dat keer op keer heeft laten zien wat er nodig is om op een commercieel levensvatbare en toch impactvolle manier te bouwen. We kijken ernaar uit om samen te werken met Ampd Energy om de sterk verminderde afhankelijkheid van diesel te realiseren. Dit is nu mogelijk met zijn innovaties.”

Ampd Energy’s Enertainer en Ampd Silo ESS bieden een schone, betaalbare, stabiele en emissievrije toekomst voor industrieën over de hele wereld, samen met waardevolle datagestuurde inzichten. Dankzij de robuuste eigen software, levert het 24/7 realtime monitoring en probleemdiagnose.

Ga voor meer informatie over Ampd Energy en zijn Enertainer en Ampd Silo ESS naar https://www.ampd.energy.

Over Ampd Energy
Ampd Energy is de drijvende kracht achter de wereldwijde energietransitie op bouwplaatsen en in zware industrieën door het creëren van geavanceerde energieopslagsystemen (ESS), connectiviteitssoftware en datawetenschap om de industriële en bouwsectoren te elektrificeren, verbinden en optimaliseren. Brandon Ng was in 2014 medeoprichter van Ampd Energy. Het bedrijf maakt slimme, volledig geautomatiseerde, emissievrije en verbonden bouwplaatsen van de toekomst mogelijk met zeer efficiënt en schaalbaar energiebeheer. Ga voor meer informatie naar https://www.ampd.energy.

Over Kibo Invest
Kibo Invest is een investeringskantoor dat zich richt op innovatie en duurzaam rendement. Via het klimaattechnologiefonds investeert het in bedrijven die een revolutie in de industrie teweegbrengen en dringende klimaatproblemen aanpakken. Het bedrijf is gevestigd in Singapore en investeert op verschillende continenten. Het maakt gebruik van zijn wereldwijde netwerk om veelbelovende ondernemingen in kaart te brengen en te ondersteunen. www.kiboinvest.com

Over Openspace 
Openspace is een investeringsbedrijf dat zich richt op Zuidoost-Azië en die transformatieve bedrijven steunt waar technologie en leven elkaar ontmoeten. Het beheert nu meer dan 800 miljoen US dollar in vier startfondsen en één groeifonds, met kantoren in Indonesië, Singapore, Vietnam, Thailand, de Filipijnen en Maleisië. Openspace investeert in verschillende sectoren, maar richt zich steeds meer op klimaattechnologie. Het portfolio omvat GoTo, Kredivo, Love, Bonito, Igloo, Finnomena, Sarisuki en Fano. www.openspace.vc

Logo – https://mma.prnewswire.com/media/2548592/AMPD_Energy_CMYK_Logo.jpg

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

CHICAGO, Nov. 4, 2024 — Nurse Capital, a venture capital firm that invests in nurse-led enterprises providing innovative solutions in healthcare, is pleased to announce its first seed-round investments in two startup businesses that serve both patients and nurses with innovative, first-of-their-kind products in the medical device and digital media platform spaces.

“As we make our first investments into these two innovative nurse-owned companies, we are not only providing capital but also deploying the strength of our carefully curated network of nurse executive leaders,” stated Nurse Capital Co-founder Beth A. Brooks, PhD, RN, FACHE. “The expertise and insights of these nurse leaders will be instrumental in accelerating the growth of these ventures, helping them navigate the complexities of healthcare and scale their impact across the industry.”

The companies are:

• Chicago-based Wave Therapeutics: Founded in 2020 by Jessica Bussert, RN, CEO, Wave Therapeutics has developed the first AI-enabled, soft robotics cushioning technology to prevent and treat pressure injuries such as bedsores which afflict 3 million Americans every year. Mobility-impaired people are especially vulnerable to pressure injuries, which can be life-threatening and are the main cause of 60,000 deaths annually. Wave Therapeutics’ patented Surf Wheelchair Cushion is designed to eliminate pressure “hot spots” on the body that can develop into bedsores. It combines a pulsing mechanism with its patented analytics platform to promote better blood flow to the heart and lungs, which is believed to properly reoxygenate affected tissues and reduce the risk of damage. Learn more at www.wavetherapeuticsinc.com.
• Los Angeles-based The Nursing Beat: Described as “theSkimm for nurses,” The Nursing Beat (TNB) is a digital media platform that produces a daily digital newsletter designed for nurses, by nurses. The platform was founded in 2019 by two ER nurses—Tamara AL-Yassin, MBA, RN and Hannah W. Berns, MHI, RN—who value speed and efficiency. Their subscription-based newsletter provides a summary of the day’s most important news and information that impact nurses, and includes valuable resources on the topics they care most about. The company also produces in-person events and professional publications targeted to nurses. Learn more at www.thenursingbeat.com

“As experienced healthcare providers themselves, the team at Nurse Capital are the perfect partners for helping to grow our business because they know firsthand the daily challenges care providers face trying to prevent and treat pressure injuries like bedsores,” stated Wave Therapeutics Founder/CEO Jessica Bussert. “Their real-world experience in this area allowed them to be able to immediately recognize the life-saving technology we’ve created to solve this healthcare crisis, which costs the US economy over $30 billion annually.”

“Nurse Capital’s belief in us and their investment are a testament to the critical role nurses play in shaping the future of healthcare,” stated The Nursing Beat’s Co-founder and CEO Tamara AL-Yassin. “We’re not just growing a media platform. We’re nurturing a community that amplifies the collective voice of nurses and drives positive change in healthcare delivery.”

Noted Nurse Capital Co-founder Marla Weston, PhD, RN, FAAN: “Nurse Capital is supporting the innovative thinking nurses bring to healthcare with the business knowledge to bring ideas to life. Together, we are empowering nurse entrepreneurs to drive meaningful change in healthcare.”

About Nurse Capital

Nurse Capital is a women-founded and managed venture capital fund based in Chicago that makes early-stage investments in nurse entrepreneurs leading high-growth-potential businesses that are transforming the future of healthcare. Co-led by veteran nurses with extensive experience as practitioners, teachers, and consultants to businesses, universities, and healthcare organizations, the firm announced the close of its inaugural $1M Nurse Founders Fund in June 2024. The Fund focuses on Late Seed and Series A investments in startups founded and led by Registered Nurses (RNs) who are launching innovative products and services that improve patient health and wellness, safety and treatment approaches. Learn more at www.nursecapital.net.

To submit a pitch deck, contact Nurse Capital at https://nursecapital.net/contact/

SOURCE Nurse Capital

WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In